Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate

Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate

Abstract Background The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration‐resistant prostate cancer (mCRPC). The majority of mCRPC patients are elderly suffering from chronic...

Full description

Bibliographic Details
Main Authors: Ondřej Fiala, Petr Hošek, Hana Korunková, Milan Hora, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti, Jindřich Fínek
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Cancer Medicine
Subjects:
abiraterone acetate
angiotensin‐converting enzyme inhibitors
antihypertensives
castration‐resistant prostate cancer
comedication
enzalutamide
Online Access:https://doi.org/10.1002/cam4.6853

Internet

https://doi.org/10.1002/cam4.6853

Similar Items